Trial Profile
A Randomized, Double-blind, Parallel-group, 26-week Study Comparing the Efficacy and Safety of Indacaterol (Onbrez Breezhaler 150 μg o.d.) With Salmeterol/Fluticasone Propionate (Seretide Accuhaler 50 μg/500 μg b.i.d.) in Patients With Moderate Chronic Obstructive Pulmonary Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Indacaterol (Primary) ; Salmeterol/fluticasone propionate
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Acronyms INSTEAD
- Sponsors Novartis Pharmaceuticals
- 30 Oct 2014 Results published in the European Respiratory Journal.
- 30 Oct 2014 Status changed from active, no longer recruiting to completed according to the Results published in the European Respiratory Journal
- 25 Apr 2014 Top-line results reported in a Novartis media release.